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Abstract: Aspects of memory involved in cognitive mechanisms were investigated in rat after oxaliplatin (OX) chemotherapy
using animal behavioural assessment of passive avoidance and social learning paradigms, which are both hippocampus-sensitive.
Rodents, previously subjected to 2-week OX treatment, showed passive avoidance and social learning impairment and apoptotic
processes in the hippocampus. Apoptosis rate significantly increased in cultured hippocampal cells exposed to OX at increasing
doses, and this effect was dose-dependent. Ex vivo experiments showed that cell damage and apoptosis were blocked in the hip-
pocampus from OX rats cotreated with copper sulphate (CS) which precludes OX transport inside the cell. In vivo, passive
avoidance and social learning impairment could not be observed in OX rats co-administered with CS. Thus, a site of action of
OX treatment on memory impairment appears to be located at the hippocampus. These findings strongly support that cellular
damage induced by OX in rodent hippocampus underlies the weakening of some memory functions.
Several studies have reported that chemotherapy could pro-
duce cognitive dysfunction. Even if mild-to-moderate cogni-
tive impairment usually occurs, it can break down quality of
life, work performance and daily activities [1]. Some studies
described the disorder as temporary; others reported difficul-
ties in cognition that could last up to 20 years after treatment
termination [2,3].
Oxaliplatin (oxalato(transl-1,2-diaminocyclohexane) (OX) is
an alkylating agent able to bind to the DNA strands causing
alterations that trigger apoptosis [4]. It has been found to pene-
trate the BBB and accumulate in both cerebrospinal and extra-
cellular fluid in the brain of non-human primate [5]. Previous
studies demonstrated that cognitive functions were modified in
behavioural tests performed in animals submitted to OX treat-
ment up to 11 months after treatment completion [6]. However,
it is presently unknown how OX might cause cognitive impair-
ments. We focused on two aspects of memory involved in cog-
nitive mechanisms such as passive avoidance and social
recognition. Hippocampus is a key structure involved in the
induction of these forms of memory [7–10]. Therefore, we
investigated in rodents how OX might cause impairment on
social memory and passive avoidance with regard to cellular
alteration induced in the hippocampus by the chemotherapeutic
agent.
Materials and Methods
Animal care. All animal manipulations were performed according to
the European community guidelines for animal care (DL 116/92,
Application of the European Communities Council Directive of 24
November 1986, 86/609/EEC; NIH publication no. 85-23, revised
1996; University of Florence assurance number: A5278-01). All
studies involving animals were in accordance with the ARRIVE
guidelines for experiments involving animals [11]. A total of 144
animals were used in these experiments. Adult (12–15 weeks) male
rats were purchased from Morini (Morini, Italy). Animals were given
food and water ad libitum and maintained under a reversed light cycle
(10:00 hr light off, 22:00 hr light on). Experiments were always
performed during the nocturnal portion of the reversed light cycle. To
minimize the number of animals used, sample size as related to
statistical significance was considered as described in Feinstein [12].
Animal treatment design. Animals were randomly attributed to the
following groups: (i) intraperitoneal (i.p.) vehicle control; (ii)
intrahippocampus (i.h.) saline control; (iii) OX; (iv) OX + CS; and (v)
CS. The OX group was administered OX dissolved in 5% glucose
solution (vehicle) (Braun, Milano, Italy) once a day at a dose of
2.4 mg/kg i.p for five consecutive days every week for 2 weeks
according a previous established protocol [13]. The vehicle control
group was administered 5% glucose solution once a day i.p. for five
consecutive days every week for 2 weeks. The OX + CS group was
co-administered i.p. OX and bilaterally i.h.-injected copper sulphate
(CS) dissolved in saline at a dose of 0.5 lg/rat. The CS group was
bilaterally i.h.-administered CS alone dissolved in saline. The 10-lg
cumulative CS dose was established to not induce toxicity in the
animals [14] and to be effective in reverting the effects of OX in the
passive avoidance and in social learning test.
Intrahippocampal administration. Animals were anaesthetized by i.p.
administration of ketamine hydrochloride (60 mg/kg) and xylazine
(4 mg/kg) and then positioned in a stereotaxic apparatus. Body
temperature was maintained with the aid of a heating pad. The depth
of anaesthesia was determined by measurement of pedal reflex. A
stainless steel cannula (22 gages) was implanted in the CA1 of the
dorsal hippocampus at 2.6 mm anterocaudal, 2 mm lateral (with
respect to the bregma) and 3.3 mm vertical coordinates according to
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the atlas of Paxinos and Watson [15]. After surgery, the rats were
allowed to recover for 7 days. The drug solutions were injected into
the hippocampus by microinjection unit attached to a 2-ll Hamilton
microsyringe via polyethylene tubing. The left and the right
hippocampus were injected with 0.5 ll of solution on each side.
Administration was controlled by an infusion pump programmed to
deliver a volume at rate of 0.1 ll over a period of 30 sec.
Behavioural tests.
Passive avoidance test. Passive avoidance learning and retention were
assessed using a step-through paradigm modelled according to Jarvik
and Koop [16]. Throughout the acquisition/conditioning phase
(training), the rat is placed in a lighted compartment. When the animal
crosses to the dark compartment, it receives a mild foot shock. During
the test phase (retention), the animal is again placed in the lighted
compartment. The differences between the second and the first entry
latency into the dark compartment were calculated. The increase in
avoidance latency indicated an improved avoidance learning
behaviour.
Social memory assessment. Social memory test is based on the
propensity of an adult rodent to inspect an unknown juvenile rodent
[17]. A never-before-met juvenile rat is placed into the home cage of
a test adult animal for 5 min. and then removed (1st exposure). After
24 hr, the same juvenile rat is placed back in the home cage together
with a novel, never-before-met juvenile rat for 5 min. (2nd exposure).
All test trials are videotaped and subsequently analysed for total body,
anogenital and perioral investigation and grooming behaviour. In the
second session, the adult rat has a free choice between the first,
already-investigated, juvenile rat and a novel unfamiliar rat. Usually,
an animal with intact social memory recalls its previous contact with
the before-met rat, and it tends to spend more time with the newly
encountered rat.
Olfaction test. Foraging test. Food was set aside from individually
housed rats for 16–24 hr before testing [18]. Then, small pieces of
chocolate were made accessible to rats for 12 hr, and chow was given
to rats when chocolate was fully eaten. Two days later, food was set
aside away for 16–24 hr. Then, the rat was transferred from his home
cage to a holding cage. Successively, a small piece of chocolate was
set on the bedding of the cage and the rat returned to his home cage.
The latency to detect chocolate chip was measured. The procedure
was repeated three more times locating small pieces of chocolate in
different positions beneath 2–3 cm of levelled bedding.
Olfactory habituation test. A Small perforate tube was filled with
cotton, added with lemon natural extract (10 ll) and placed in the
cage of each rat for 1 min. [19]. The procedure was repeated four
times at 10-min. intervals. In a 10-min. later trial, vanilla natural
extract (10 ll) was added to lemon in the tube which was set in the
rat cage. Olfactory investigation (nasal contact with the tube) was
recorded.
Motor co-ordination and exploratory ability tests. Groups of rats
treated with all the drugs used in the above experiments were
submitted to rotarod [20] and hole-board [20] behavioural tests. In the
rotarod test, the rat was placed on a horizontal rotating rod; the animal
must walk forward to remain upright and not fall off. The balance
time before falling was measured over time. The cut-off time for each
measurement was set at 30 sec. The hole-board apparatus consists of
an enclosed space, the floor of which has sixteen holes in a grid
pattern. The rodent, when placed in the apparatus, is free to dip its
head through the holes in the floor; the frequency and duration of this
behaviour are thought to measure levels of exploratory behaviour.
Oligonucleosomal ELISA. Primary hippocampal cell lines (Life
Technologies, Milan, Italy) were cultured according to the
manufacturer’s instructions. Briefly, cells were cultured on tissue
culture flasks in complete neurobasal medium (Thermo Fisher,
Waltham, MA, USA) at 37°C in air supplemented with 5% CO2-
humidified conditions. Cells were seeded at a density of
1 9 104 cells/well in 200 ll, washed three times with neurobasal
medium and exposed to OX at different concentrations for 48 hr at
+37°C. All experiments were performed in triplicate, a minimum of
three times. DNA fragmentation generated during apoptosis in
response to OX treatment was detected using a sandwich enzyme
immunoassay system (Cell Death Detection ELISA; Roche, Monza,
Italy) that allowed specific determination of mono- and
oligonucleosomes in the cytoplasmic fraction of cell lysates. The
amount of DNA fragments was determined colorimetrically with the
ABTS ELISA Peroxidase Substrate (2,20-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid)) (Life Technologies) using a
microplate reader at 405 nm with a reference filter of 490 nm.
Absorbance values were calculated and reported as per cent of control.
Study of apoptosis factors ex vivo.
Measurement of caspase-3 and caspase-9 activities. Caspase-3 and
caspase-9 were determined by colorimetric kit (Abcam, Cambridge,
UK; MBL, Woburn, MA, USA) following the manufacturer’s
instructions. All the animals were deeply anaesthetized using thiopental
(50 mg/kg, i.p.), and hippocampus tissues were isolated. Homogenate
cells were centrifuged at 450 9 g for 10 min., and the supernatant was
recentrifuged at 12,000 9 g for 10 min. The extracts, each containing
100 lg protein, were mixed with 50 ll of 29 reaction buffer/
dithiothreitol (DTT). Next, 5 ll (1 mM) of protein substrate (DEVD-
pNA for caspase-3 and LEHD-pNA for caspase-9) was added to each
reaction and incubated at 37°C for 3 hr. Light emission of pNA was
quantified using an ELISA reader (wavelength: 400–405 nm).
Absorbance of pNA in the treated as compared to control groups was
used as measure of the apoptotic activity. Protein concentration was
determined by Protein DC Assay Kit (Bio-Rad, Milan Italy).
Measurement of Bax and Bcl-2 content. ELISA kit containing
microtiter plate pre-coated with an antibody specific to Bax and Bcl-2
was used to measure Bax and Bcl-2 content (Antibodies-online Inc.,
Fig. 1. Time course of rat body-weight in the treatment period. Verti-
cal bars represent S.E.M. Reported numbers represent the number of
animals used for each experimental group. F4,55 = 1.18, n.s.
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Atlanta, GA, USA). Hippocampal tissue was rinsed with 1 9 PBS
(phosphate-buffered saline), homogenized in 1 ml of 1 9 PBS and
stored overnight at 20°C. After two freeze–thaw cycles, homogenates
were centrifuged for 5 min. at 5000 9 g at 2–8°C and supernate was
immediately assayed. A total of 100 ll of standard or unknown sample
solution was added to each well with the biotin-conjugated antibody
preparation. After 2-hr incubation (37°C) and washing (three times),
100 ll of avidin conjugated to horseradish peroxidase was added to
each microplate well and incubated for 30 min. (37°C). After washing,
90 ll of TMB (3,30,5,50-tetramethyl-benzidine) substrate solution was
added to the well and incubated for 15–25 min. (37°C). Finally, the
enzyme–substrate reaction was terminated by the addition of a 50 ml
stop solution, and colour change was measured spectrophotometrically
reading at 450 nm wavelength. Protein concentration in unknown
samples was determined using standard curve (achieved by standard
solution) and expressed as pg/ml.
Cytosolic cytochrome expression. Mitochondrial fraction from rat
hippocampus was obtained using Mitochondria Isolation Kit (Sigma,
Milan, Italy). Protein extraction of both the mitochondrial and
cytosolic fractions was performed from hippocampal tissue of rats
under different treatment conditions. Samples were submitted to
Western blot according to the procedure previously described [21].
The primary antibody was at 1:1000 dilution of cytochrome c
monoclonal (PharMingen, San Diego, CA, USA).
Histological control. At the conclusion of the behavioural
experiments, 1% Evans blue dye was administered to rats according to
Fig. 2. Entry latency into the dark compartment in the passive avoid-
ance test is shown at the end of OX treatment in the presence or
absence of CS. Entry latency values were measured in the training test
(T) and after 24 hr in the retention test (R). The numbers shown in
the figure represent the number of animals used in each experiment.
Vertical lines represent S.E.M. **a < 0.01 and ^^a < 0.01 in compar-
ison with corresponding vehicle and saline controls, respectively.
F4,54 = 5.72, a < 0.001.
Fig. 3. Investigation times of juvenile by adult rat are shown during
the first exposure and on re-exposure after 24 hr. Data are shown for
familiar (F) and unfamiliar (U) rat after 2-week OX treatment. The
same experiment was repeated in OX rats cotreated with CS. The
numbers shown in the figure represent the number of animals used in
each experiment. Vertical lines represent S.E.M. **a < 0.01 and
^^a < 0.01 in comparison with corresponding vehicle and saline con-
trols, respectively. F4,54 = 6.12, a < 0.001.
© 2016 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
OXALIPLATIN INDUCED COGNITIVE WEAKENING 3
the microinjection procedure for i.h. administration. A post-mortem
histological control of the location of cannula inside the hippocampus
was performed on cryostat sections of unfixed brains observed under
stereomicroscope (Leica MZ12.5; Leica, Solms, Germany). Data of
any rat were excluded from statistical analysis if the cannula tip was
outside the CA1 region of the hippocampus or if the region had
sustained extensive damage.
Statistics. All experimental results were presented as mean  S.E.M.
Analysis of variance (ANOVA) followed by Fisher’s protected least
significant difference procedure for post hoc comparison was used to
verify significance between two means of behavioural tests or
apoptotic process investigation. Data were analysed with the StatView
software for the Macintosh (1992). A significance level (a) <0.01 was
considered significant.
Results
Effect of OX on rat weight.
Before initiation of OX administration, rat groups were
weighed in grams, respectively, 195  8.0 (vehicle i.p. con-
trol), 202.4  7.3 (saline i.h. control), 198  8.1 (OX),
209  8.7 (OX + CS) and 205  7.3 (CS). Statistical com-
parison between groups showed that the treated and control
groups gained weight not significantly differently throughout
the 2 weeks of treatment although the weight increase was
lower in the OX-treated rats (fig. 1). Weight was not statisti-
cally different in animals that had finished OX treatment
3 weeks before (fig. 1).
Effect of OX and CS on passive avoidance and social
learning.
In the passive avoidance test, OX rats showed a second
latency significantly lower than the control rats (fig. 2); in the
social learning test, the time spent by the adult rat in
investigating a familiar juvenile rat was not significantly dif-
ferent from the time spent investigating an unfamiliar rat
(fig. 3). When CS was co-administered with OX, passive
avoidance and social recognition behaviour were not signifi-
cantly different from controls (figs 2 and 3). Social learning
and passive avoidance appeared both impaired in rats that had
finished OX treatment 3 weeks before (fig. 4).
Olfactory tests.
The time spent in locating a preferred food hidden in bedding
by rats treated with OX in the presence/absence of CS or pre-
viously submitted to intracranial surgery was not different
from that spent by control animals (fig. 5A). The same treat-
ments did not modify the amount of time spent investigating a
lemon-scented cylinder during repeated 1-min. presentations,
as compared to the values obtained in the control rats
(fig. 5B). All rats showed dishabituation when vanilla was
added to lemon inside the cylinder (fig. 5B).
Effect of treatment on rat motor behaviour.
The endurance time on the rotating rod evaluated before and
after OX treatment in the presence or absence of CS indicated
a lack of any impairment in the motor co-ordination of the
treated rats; spontaneous motility as well as inspection activity
was unmodified by treatments (fig. 6).
Histology.
Of the rats that received intracranial injections, three were
excluded from statistical analysis because of misplacement.
Five rats were excluded for necrosis. Inspection of the remain-
ing brain sections revealed that dye injections were centred
within the CA1 hippocampal region (fig. 7).
Fig. 4. Result of passive avoidance (A) and social memory test (B) performed in rats 3 weeks after the end of OX treatment. Vertical lines repre-
sent S.E.M. Ten rats were used for each experimental condition. **a < 0.01 in comparison with corresponding vehicle control.
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Cultured cell apoptosis.
The amount of mono- and oligonucleosomes in the cytoplas-
mic fraction of cell lysates was quantitatively assessed (fig. 8).
Fig. 5. Olfactory-guided behaviour in rat measured at the end of OX treatment in the presence or absence of CS. (A) Time required by rats to find
small pieces of chocolate on the surface or beneath smoothed wood-chip bedding, in three successive trials. (B) Amount of time spent investigating
a lemon-scented cylinder during repeated 1-min. presentation training time in the presence of lemon alone or lemon/vanilla combination. Vertical
lines represent S.E.M. The number reported on the top of the bar graph represents the number of animals used in each experimental condition. A:
F4,54 = 1.41, n.s.; B: F4,54 = 1.21, n.s.
Fig. 6. Lack of effect by OX, OX + CS, CS, vehicle and saline controls on motor co-ordination in the rotarod test (left). Lack of effect by OX,
OX + CS, CS, vehicle and saline controls on spontaneous motility and exploratory activity (right) in the hole-board test. The tests were per-
formed at the end of OX treatment in the presence or absence of CS. Vertical lines represent S.E.M. The number of animals used in each exper-
imental condition is represented in the figure. Motor co-ordination: F4,54 = 1.10, n.s. Motility: F4,54 = 1.72, n.s. Exploratory activity:
F4,54 = 1.98, n.s.
Fig. 7. Schematic representation of microinfusion site distribution
within (♦) and outside (x) CA1 hippocampal area of brain of rat. The
number of the symbols is less than the total number of rats because of
overlaps.
Fig. 8. The amount of cytoplasmic mono- and oligonucleosomes is
represented in hippocampal cells incubated with increasing concentra-
tions of OX for 48 hr. Each bar represents per cent of control and is
obtained from three independent experiments. Reported S.E.M. were
obtained from untransformed data. *a < 0.05 and **a < 0.01 in com-
parison with untreated cells. F4,10 = 7.13, a < 0.001.
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Control culture showed little DNA fragmentation, whereas
cells previously treated with OX for 48 hr showed signifi-
cantly more mono- and oligonucleosomes at higher OX doses
(fig. 8).
Apoptosis marker ex vivo.
The levels of caspase-3, caspase-9 and Bax apoptotic proteins
significantly increased in the hippocampus from the OX-trea-
ted rats as compared to controls (figs 9 and 10). Intracranial
co-administration of CS with OX could prevent apoptotic pro-
tein increase (figs 9 and 10). In the OX group, Bcl-2 levels
were significantly lower than those of the control group,
whereas they returned to control values in the presence of CS
(fig. 10). OX induced a mitochondrial derangement measured
as cytosolic release of cytochrome c which was reversed by
CS administration (fig. 11).
Discussion
Our experiments have confirmed that repeated treatment with
OX induces a cognitive deficit in rat. Lack of any significant
decrement in the investigation time taken by the adult rat
between the first and second exposure to the juvenile rat
demonstrated that social memory formation appeared to be
impaired when adult rat was previously subjected to 2-week
treatment with OX. It is well known that olfactory system
plays a main role in processing olfactory signals relevant to
social discrimination [22]. Investigatory behaviour examined
in social learning test included direct contact or sniffing, nos-
ing or generally inspecting any body surface of the novel
juvenile rat. We were not able to detect any OX-induced alter-
ation in olfactory system of the rats subjected to treatment
with the anticancer drug, and therefore, we can exclude that
olfactory system impairment has affected the test. Investigation
of passive avoidance paradigm revealed that animals previ-
ously subjected to 2-week OX treatment developed difficulty
in consolidating memory of an unpleasant experience linked
to a dark space environment which rodents preferentially
explore due to their innate preference of obscurity. Control
animals that learned the task avoided the location paired with
the aversive stimulus when the possibility of exploring it was
offered for the second time. Otherwise, rats previously treated
with OX were not able to remember the unpleasant experience
associated with the dark space, and the entry latency into this
was significantly shorter compared to untreated rats. We
observed that OX treatment does not induce any alteration of
the motor activity and does not interfere with the exploratory
activity of the rats excluding any misinterpretation of results
due to these factors.
Fig. 9. Effect of 2-week OX treatment in the presence or absence of
CS on caspase-3 and caspase-9 activity in rat isolated hippocampal tis-
sue. Each bar represents the mean  S.E.M. of measured caspase
activity and is obtained from four independent experiments, each one
made from the tissue of three rats. **a < 0.01 and ^^a < 0.01 in
comparison with corresponding vehicle and saline controls, respec-
tively. Caspase-3: F4,10 = 12.07, a < 0.001. Caspase-9: F4,10 = 16.87,
a < 0.001.
Fig. 10. Change in Bax and Bcl-2 content in hippocampus tissue from
rats which underwent 2-week OX treatment. Each bar represents the
mean  S.E.M. of measured Bax and Bcl-2 concentration in cytosolic
fraction. Bax/Bcl-2 ratio is reported in the lower part of the figure.
*a < 0.05, **a < 0.01, ^a < 0.05, ^^ a < 0.01, in comparison with
vehicle and saline controls. Bax: F4,10 = 14.19, a < 0.001. Bcl-2:
F4,10 = 7.19, a < 0.01
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Previous observations that OX has well-described neurotoxic
effects [23], penetrates the blood–brain barrier and accumulates
in the CNS [5] make conceivable that the drug might have a
direct effect on brain function. Hippocampus has been demon-
strated as the centre of learning and memory in the CNS
[24,25]. The ability to make passive avoidance responses was
impaired in animals with ablation of the hippocampus [10]. This
area plays also a main role in memory for odours on which
social learning paradigm is based. Particularly, field CA1 in the
hippocampus has been shown to send axons to the main olfac-
tory bulb, the anterior olfactory nucleus and the primary olfac-
tory cortex [26]. The OX-induced memory impairment revealed
by our experiments is consistent with hippocampal damage, and
therefore, we considered it as an appropriate area for studying
the mechanisms involved in the cognitive aspects investigated
by our study. In experiments in vitro, apoptosis rate dose-depen-
dently increased in cultured hippocampal cells exposed to OX,
as compared to untreated cells. These results were confirmed
ex vivo in hippocampal tissue from rats exposed to 2-week OX
treatment. We followed, as a guideline for exploring the apop-
totic process, OX-induced apoptotic pathway previously shown
in colon cancer cells [27]. Activity of main initiator of apoptosis
as caspase-3 and caspase-9 was significantly increased in the
hippocampus from OX-treated rats. A decreased expression of
the anti-apoptotic protein Bcl-2 could be observed, which corre-
sponds to a significant increased expression of Bax, a pro-apop-
totic protein which, following an apoptotic stimuli, translocates
from cytoplasm to mitochondrial membranes mediating the
release of cytochrome c. As expected, cytochrome c release
could be observed in hippocampal cytosolic fraction from the
OX-treated rats. Apoptotic processes were not activated in the
hippocampus of rats treated with OX plus CS, a blocker of OX
entrance within cells through inhibition of CTR1, a channel-like
transporter, localized to the neuronal surface, previously identi-
fied as a carrier for OX into the cell [28,29]. When CS was
delivered locally at both hippocampal sites through bilateral
[30] intracranial injections performed concurrently with OX
systemic administration, rat hippocampal tissue showed pro-
apoptotic caspase expression levels comparable with those of
controls, and cytochrome c content in mitochondrial cell frac-
tion was not decreased. Bax and Bcl-2 relative amount was
unmodified with regard to controls. Social memory and passive
avoidance paradigms were explored in vivo when OX was pre-
vented to be taken up by hippocampal cells. After 2-week OX
treatment in the presence of CS, memory could be consolidated
during spontaneous exploration of a novel environment in pas-
sive avoidance test, and the knowledge of a new individual
could be acquired in social learning behaviour.
Taking our data as a whole, our findings show that a site of
action of OX on the two forms of memory explored in this
study is located at the hippocampus. At this supraspinal site,
cellular damage induced by OX in this brain area could under-
lie the weakening of some memory functions in rat.
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